Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 530617 | NSE Symbol : | ISIN : INE375C01014 | Industry : Food - Processing - Indian |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
08-Feb-2025	13-Feb-2025	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Intimation of Board meeting to consider and approve unaudited standalone and consolidated financial results of the company for the quarter ended 31 December 2024 and proposal for raising of funds. Please find attached the financial results for the quarter and nine months ending December 31, 2024. (As Per BSE Announcement Dated on: 13/02/2025)
09-Nov-2024	14-Nov-2024	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Unauidted Finanicals results for the quarter ended September2024. To Raise funds by way of issue of eligible securities by way of preferential issue Results for the quarter and half year ended September 2024 (As Per Bse Announcement Dated on 14.11.2024) Further to the communication received from the BSE, the company has uploaded the revised financial results for the Quarter and Half-Year ended 30 September 2024. The nature of change is only in the format of the Limited Review Report of the Consolidated Financial Statements which is in line with the applicable SEBI Circular(s). The financial figures and other information remain unchanged. (As Per BSE Announcement Dated on 03.01.2025)
14-Nov-2024	13-Nov-2024	Preferential Issue	Allotment of 840000 warrants on preferential basis at a price of INR 60.50 with each warrant convertible into 1 equity share of face value of INR 10 per share fully paid up.
04-Nov-2024	04-Nov-2024	Change in Directors	The Board at its meeting held today i.e November 04, 2024 inter alia considered and approved the followings items:
06-Aug-2024	13-Aug-2024	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve unaudited financial results for first quarter and three months ended 30th June 2024 Copy of unaudited financial results for first quarter and three months ended 30th June, 2024 along with Limited Review Report in compliance with Reg 33 of the SEBI (LODR) Regulations, 2015. (As per BSE Announcement dated on 13/08/2024)
25-Jun-2024	28-Jun-2024	Issue of FCCB	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/06/2024 inter alia to consider and approve issuance of Foreign Currency Convertible Bonds (FCCBs) Further Company has entered into Subscription Agreement with the Lead Arranger - Aries Capital Limited an Investment Manager company appointed for the purpose of the FCCB issue.
21-May-2024	30-May-2024	Accounts	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve audited financial results for fourth quarter and financial year ended 31st March 2024. In compliance with Reg 33 of SEBI LODR, Audited financial results along with Audit Report and Declaration attached for fourth quarter and financial year ended 31.03.2024 (As per BSE Announcement Dated on 30/05/2024)
22-Apr-2024	22-Apr-2024	Conversion	Pursuant to Reg 30 of SEBI LODR, Board of Directors in just concluded meeting have considered and approved allotment of 17,00,000 equity shares of Rs.10/- each as fully paid up shares at a price of Rs. 36/- per share consequent upon conversion of 17,00,000 warrants upon exercise of conversion right option. 5,00,000 outstanding warrants are forfeited due to non-exercise of option.
05-Feb-2024	12-Feb-2024	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve Un-audited financial results for third quarter and nine months ended 31st December 2023 UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ADN NINE MONTHS ENDED 31ST DECEMBER, 2023 DULY APPROVED BY THE BOARD AT THEIR MEETING HELD ON 12.2.2024 (As Per BSE Announcement dated on 12.02.2024)
06-Nov-2023	14-Nov-2023	Quarterly Results	Quarterly Results & Preferential Issue of shares SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 ,inter alia, to consider and approve unaudited financials results for second quarter and half year ended 30.09.2023 and to consider further issue of shares by way of preferential allotment to promoter and others (As Per BSE Announcement dated on 06.11.2023) Board of Directors in their just concluded Board meeting has decided to issue and allot Convertible Warrants of the Company on a Preferential Basis to Promoters, KMP and Identified Investors towards raising of additional capital by the Company pursuant to Section 42, 62 of the Companies Act, 2013 and as per the SEBI (Issue of Capital and Disclosure Requirement) Regulation, 2018 ['SEBI (ICDR) Regulations, 2018'] subject to the approval of the members in the Extra Ordinary General Meeting and appropriate authorities. Extra Ordinary General Meeting of the Company to be convened on Friday, 8th December 2023 at 11.00 A.M., through Video Conferencing/ Other Audio Visual Means (OAVM) . The details as required for Preferential Issue under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI circular bearing reference no. CIR/ CFD/CMD/4/2015 dated 9th September, 2015 is enclosed Board in their meeting concluded has considered and adopted unaudited financials results for 2nd quarter and half year ended 30th September, 2023. A copy of same along with Limited Review Report is enclosed (As Per BSE Announcement Dated on 14/11/2023)
07-Aug-2023	14-Aug-2023	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve Un-Audited Financial Results of the Company for first quarter and three months ended 30th June 2023. Un-audited financial results for first quarter and three months ended 30th June, 2023 along with Limited Review Reports enclosed in compliance with the Regulation 33 of SEBI (LODR) Regulations. 2015 (As Per BSE Announcement Dated on 14.08.2023)
22-May-2023	30-May-2023	Accounts	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve audited financial results for fourth quarter and financial year ended 31st March 2023. In compliance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 below mentioned documents are enclosed herewith for your immediate reference. 1. Audited financial results in accordance with Schedule III format of Companies Act, 2013. 2. Auditors' Report pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 3. Declaration pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 (As Per BSE Announcement dated on 30.05.2023)
02-Feb-2023	09-Feb-2023	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve Un-audited financial results for third quarter and nine months ended 31st December 2022. Un-audited financial results for third quarter and nine months ended 31st December, 2022 along with Limited Review Report is enclosed herewith in compliance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 09/02/2023)
07-Nov-2022	12-Nov-2022	Quarterly Results	SAMPRE NUTRITIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve 1. Un-audited financial results for second quarter and half-year ended 30th September 2022. 2. Setting up of wholly owned subsidiary in UAE. Board consider and adopted Un-audited Financial results for the quarter and half year ended 30.09.2022 and approved other matters as detailed in the outcome of board meeting. (As Per BSE Announcement Dated 12.11.2022)
20-Oct-2022	20-Oct-2022	Preferential Issue	With reference to the captioned subject, we wish to inform you that the Board of the Directors of the Company at their meeting held today i.e., Thursday, 20th October, 2022 has considered and approved the following: 1. Allotment of 20,50,000 Equity Shares of Face Value of ? 10/- each at a premium of ? 26/- each amounting to Rs. 7,38,00,000/- to Strategic Investors being Non-Promoters on Preferential Allotment basis 2. Allotment of 26,00,000 Convertible Warrants of Face Value of ? 10/- each at a premium of ?. 26/- each to Strategic Investors being Non-Promoters on Preferential Allotment basis pursuant Resolution passed in the Extra Ordinary General Meeting held on August 13, 2022 incompliance with the provisions of Section 42, 62 and other applicable provisions of The Companies Act, 2013. Further details enclosed in the attachment.

1 2

LOGIN HERE

Sampre Nutritions Ltd

Board Meeting